Back to News
Market Impact: 0.2
Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & OutlookCompany Fundamentals
Teva CEO Richard Francis said the company has moved from the initial phase of its "Pivot to Growth" plan into its next stage. Management cited momentum across branded medicines, innovation, generics and biosimilars, alongside improved financial flexibility, although no financial metrics or revised targets were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
TEVA0.55
More News
- US estrogen supply crunch widens as women seek alternatives to scarce patches
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Fortinet’s stock is taking a dive after earnings. Here’s why.
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- Microsoft's Big Bets on AI Start to Pay Off